Alnylam Pharmaceuticals
ALNY
HK$2,472
Share price
-2.39%
Change (1 day)
21.31%
Change (1 year)
Categories
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.
Alnylam Pharmaceuticals (ALNY) - Total debt
Total debt on the balance sheet as of March 2025 : HK$10.21 Billion
According to Alnylam Pharmaceuticals 's latest financial reports the company's total debt is HK$10.21 Billion. A company’s total debt is the sum of all current and non-current debts.
Alnylam Pharmaceuticals - Total debt on balance sheet (from 2003 to 2025)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2024-12-31 | HK$10.06 B | -1.31% |
| 2023-12-31 | HK$10.19 B | -1.17% |
| 2022-12-31 | HK$10.31 B | 32.61% |
| 2021-12-31 | HK$7.77 B | 92.53% |
| 2020-12-31 | HK$4.04 B | 70.75% |
| 2019-12-31 | HK$2.36 B | 907.21% |
| 2018-12-31 | HK$0.23 B | 0.23% |
| 2017-12-31 | HK$0.23 B | -79.85% |
| 2016-12-31 | HK$1.16 B | |
| 2007-12-31 | HK$52.69 M | -25.84% |
| 2006-12-31 | HK$71.05 M | 23.93% |
| 2005-12-31 | HK$57.33 M | 2.46% |
| 2004-12-31 | HK$55.96 M | 288.36% |
| 2003-12-31 | HK$14.4 M |
Total debt for similar companies or competitors
| Company | Total debt/th> | differencediff. | Country |
|---|---|---|---|
 Arrowhead Pharmaceuticals
ARWR | HK$3.04 B | -70.17% | 🇺🇸 USA |
 Regeneron Pharmaceuticals REGN | HK$21.23 B | 107.80% | 🇺🇸 USA |
 Sarepta Therapeutics
SRPT | HK$10.54 B | 3.24% | 🇺🇸 USA |
 OPKO Health
OPK | HK$3.86 B | -62.13% | 🇺🇸 USA |
 Regulus Therapeutics RGLS | HK$10.99 M | -99.89% | 🇺🇸 USA |
 Novartis NVS | HK$245.45 B | 2,302.35% | 🇨🇭 Switzerland |
 Sanofi SNY | HK$178.73 B | 1,649.37% | 🇫🇷 France |
 Teva Pharmaceutical Industries TEVA | HK$132.96 B | 1,201.36% | 🇮🇱 Israel |